Skip to main content
. 2011 May;18(5):807–814. doi: 10.1128/CVI.00434-10

Fig. 2.

Fig. 2.

OVA-CTLA-4 binds to B7 ligands on DCs in vitro. (A) Purified OVA (lane 2) and OVA-CTLA-4 (lane 3) were determined by Western blot analysis. Lane 1, protein markers. (B) DCs were treated with OVA or OVA-CTLA-4 and lysed for immunoprecipitation with the anti-CD80 antibody. Precipitated proteins were determined by Western blot analysis with anti-OVA antibody. OVA was observed in the OVA-CTLA-4 treated group, whereas no protein was observed in the OVA-treated group. (C) DCs were treated with OVA or OVA-CTLA-4 and lysed for immunoprecipitation with the anti-CD86 antibody. Precipitated proteins were determined by Western blot analysis with anti-OVA antibody. OVA was observed in the OVA-CTLA-4-treated group, while no protein was observed in the OVA-treated group.